Clinical Outcomes of Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Patients with Lymph Node Metastases from Gynecological Cancers.
gynecological cancer
lymph nodes
oligometastases
stereotactic body radiotherapy
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Jan 2023
27 Jan 2023
Historique:
received:
02
01
2023
revised:
22
01
2023
accepted:
26
01
2023
entrez:
25
2
2023
pubmed:
26
2
2023
medline:
26
2
2023
Statut:
epublish
Résumé
To evaluate clinical outcomes of stereotactic body radiation therapy (SBRT) as a local treatment for lymph node metastases from gynecological cancers. Between November 2007 and October 2021, we retrospectively analyzed 29 lymph node metastases in 22 oligometastatic/oligoprogressive patients treated with SBRT. The Kaplan-Meier method was used to estimate the rates survival. Univariate analysis for prognostic factors were performed with the log-rank test, and Cox proportional hazards regression was used to estimate hazard ratios (HR). Median age was 62 years (IQR, 50-80 years). Median follow-up was 17 months (IQR 10.5-31 months). The median survival was 22 months (CI 95%: 4.2-39.7, IQR: 12.5-34.5 months). Six months, one year and two year overall survival (OS) were 96.6%, 85.2%, and 48.7%, respectively. Median local control (LC) was not reached. Six months, 1one year and 2 year were 93.1%, 87.9%, and 79.9%, respectively. Distant metastasis free survival (DMFS) at one year, and two year was 53% and 37.1%, respectively Four patients (18%) experienced acute G1-G2 toxicities. No G3-4 acute toxicity was reported, and no late toxicity was observed. SBRT for lymph node recurrence offers excellent in-field tumor control with safe profile and low toxicities. Size, number of oligometastases, and time primary tumor to RT seem to be significant prognostic factors.
Sections du résumé
BACKGROUND
BACKGROUND
To evaluate clinical outcomes of stereotactic body radiation therapy (SBRT) as a local treatment for lymph node metastases from gynecological cancers.
METHODS
METHODS
Between November 2007 and October 2021, we retrospectively analyzed 29 lymph node metastases in 22 oligometastatic/oligoprogressive patients treated with SBRT. The Kaplan-Meier method was used to estimate the rates survival. Univariate analysis for prognostic factors were performed with the log-rank test, and Cox proportional hazards regression was used to estimate hazard ratios (HR).
RESULTS
RESULTS
Median age was 62 years (IQR, 50-80 years). Median follow-up was 17 months (IQR 10.5-31 months). The median survival was 22 months (CI 95%: 4.2-39.7, IQR: 12.5-34.5 months). Six months, one year and two year overall survival (OS) were 96.6%, 85.2%, and 48.7%, respectively. Median local control (LC) was not reached. Six months, 1one year and 2 year were 93.1%, 87.9%, and 79.9%, respectively. Distant metastasis free survival (DMFS) at one year, and two year was 53% and 37.1%, respectively Four patients (18%) experienced acute G1-G2 toxicities. No G3-4 acute toxicity was reported, and no late toxicity was observed.
CONCLUSIONS
CONCLUSIONS
SBRT for lymph node recurrence offers excellent in-field tumor control with safe profile and low toxicities. Size, number of oligometastases, and time primary tumor to RT seem to be significant prognostic factors.
Identifiants
pubmed: 36836463
pii: jpm13020229
doi: 10.3390/jpm13020229
pmc: PMC9965700
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Clin Oncol. 2014 Jun;37(3):227-33
pubmed: 22992626
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Radiother Oncol. 2009 Oct;93(1):14-7
pubmed: 19409636
Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):442-8
pubmed: 11567819
Int J Gynecol Cancer. 2017 Feb;27(2):396-402
pubmed: 28114239
Gynecol Oncol. 2012 Jan;124(1):42-7
pubmed: 22014627
Int J Radiat Oncol Biol Phys. 2009 May 1;74(1):147-53
pubmed: 18990511
Int J Gynecol Cancer. 2020 Jun;30(6):865-872
pubmed: 32273293
Oncol Rep. 2009 Aug;22(2):415-9
pubmed: 19578785
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6
pubmed: 7713792
Int J Gynecol Cancer. 2018 Oct;28(8):1507-1513
pubmed: 30036231
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1043-7
pubmed: 7713775
JCO Oncol Pract. 2022 Jun;18(6):417-422
pubmed: 35286157
Gynecol Oncol. 2020 Nov;159(2):573-580
pubmed: 32917412
J Gynecol Oncol. 2018 Jan;29(1):e11
pubmed: 29185269
BMC Cancer. 2020 Jun 9;20(1):540
pubmed: 32517673
Front Oncol. 2016 Nov 22;6:249
pubmed: 27921006
Oncologist. 2020 Feb;25(2):e311-e320
pubmed: 32043791
World J Radiol. 2014 Jun 28;6(6):366-73
pubmed: 24976937
Int J Radiat Oncol Biol Phys. 2022 Nov 15;114(4):611-616
pubmed: 35643253
Int J Gynecol Cancer. 2017 Feb;27(2):403-408
pubmed: 27870704
Rep Pract Oncol Radiother. 2015 Nov-Dec;20(6):472-83
pubmed: 26696788
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
Front Oncol. 2012 Dec 05;2:181
pubmed: 23227452
Radiology. 2016 Aug;280(2):576-84
pubmed: 26909647
Cancer Diagn Progn. 2021 May 3;1(2):53-60
pubmed: 35403131
Clin Oncol (R Coll Radiol). 2017 Jun;29(6):378-384
pubmed: 28209456
J Clin Oncol. 2019 Jun 20;37(18):1558-1565
pubmed: 31067138
In Vivo. 2020 Sep-Oct;34(5):2587-2593
pubmed: 32871788